Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 154

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 154
---
 directors were selected. See “Related Party Transactions” for additional information.

Compensation

The following table presents
in the aggregate all compensation we paid to all of our directors and senior management as a group for the year ended December 31, 2024.
The table does not include any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during
this period.

All amounts reported in the
table below reflect our cost, in thousands of U.S. dollars. Amounts paid in NIS are translated into U.S. dollars at the rate of NIS 3.67
= U.S. $1.00, based on the average representative rate of exchange between the NIS and the U.S. dollar as reported by the Bank of Israel
during such period of time.

|                                                     |     | Salary,                      
 bonuses and Related Benefits |         |     | Pension, Retirement and 
 Other Similar Benefits  |   |     | Share           
 Based           
 Compensation(1) |   |
|:----------------------------------------------------|:----|:-----------------------------|--------:|:----|:------------------------|:--|:----|:----------------|:--|
| All directors and senior management as a group,     
 consisting of five persons as of December 31, 2024. |     | $                            | 218,000 |     | $                       | - |     | $               | - |

<div align='center'>93</div>

For
so long as we qualify as a foreign private issuer, we will not be required to comply with the proxy rules applicable to U.S. domestic
companies regarding disclosure of the compensation of certain executive officers on an individual basis. Pursuant to the Companies Law,
we will be required, after we become a public company, to disclose the annual compensation of our five most highly compensated officers
on an individual basis. This disclosure will not be as extensive as that required of a U.S. domestic issuer. We intend to commence providing
such disclosure, at the latest, in the annual proxy statement for our first annual meeting of shareholders following the closing of this
offering, which will be filed under cover of a report on Form 6-K.

As
of June 30, 2025, options to purchase 37,500 Ordinary Shares granted to one of our directors were outstanding under our Option Plan at
an exercise price of $3.97 per share. The following table sets forth information regarding options granted to our executive officers
and directors during